BMRN · Intrinsic value
Is BioMarin Pharmaceutical Inc. (BMRN) overvalued or undervalued?
BioMarin Pharmaceutical Inc. (BMRN) trades at the delayed market price of $54.68 a share. That price already implies revenue growth of 18.1% a year for 5 years. TickerWorth's fair value is $70.83 a share (priced within our range of $46.63 – $109.11). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is BMRN fairly valued?
- Fair value
- $70.83
- Market price
- $54.68
- Upside to fair value
- +29.5%
- Verdict
- Priced within our range of $46.63 – $109.11
Reverse DCF: Today's price implies revenue growth of 18.1% a year for 5 years; our model assumes 11.8% a year on average over the same horizon.
What is BMRN's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: trades below our estimate of what it's worth. Its weakest: balance sheet looks stretched.
- Value · 43 of 100
Cheaper than 43% of Healthcare companies in US
- Price vs worth · 74 of 100
- Quality · 46 of 100
More profitable than 46% of Healthcare companies in US
- Financial health · 34 of 100
Financially stronger than 34% of Healthcare companies in US
- Growth · 60 of 100
Growing faster than 60% of Healthcare companies in US
- Momentum · 38 of 100
Outperformed 38% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
BMRN DCF valuation, input by input
TickerWorth's fair value for BioMarin Pharmaceutical Inc. (BMRN) is $70.83 a share, against the delayed market price of $54.68 (priced within our range of $46.63 – $109.11). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values BMRN at about $46.63 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts BioMarin Pharmaceutical Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 6.2%, with a long-run terminal growth rate of 2.5%. About 85% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 18.1% annual revenue growth for BMRN. Our base case instead compounds to about 11.8% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, BMRN's modeled DCF value ranges from about $22.09 to $170.64 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what BioMarin Pharmaceutical Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of BMRN's intrinsic value. Figures update as new filings and prices come in.
Every input behind BMRN's DCF
| Input | Value |
|---|---|
| Base-year revenueBIOMARIN PHARMACEUTICAL INC FY2025 10-K (accession 0001048477-26-000004): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $3,221,250,000 |
| Base EBIT marginBIOMARIN PHARMACEUTICAL INC FY2025 10-K (accession 0001048477-26-000004): us-gaap:OperatingIncomeLoss 409,478,000 / revenue 3,221,253,000 = 12.71%, FY2025. | 12.7% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 20% → 16% → 12% → 8% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 4.7% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.40 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesBIOMARIN PHARMACEUTICAL INC FY2025 10-K (accession 0001048477-26-000004): WeightedAverageNumberOfDilutedSharesOutstanding = 197,394,000 shares, FY2025. | 197M |
| Market priceBackup price feed · as of 2026-10-19 12:46 UTC | $54.68 |
Change BMRN's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does BioMarin Pharmaceutical Inc. do?
What does it do?
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 3,221 people.
How does it make money?
The business turns $3.4B in annual revenue into profit. Out of every $100 of sales, about $21 is left as operating profit (operating margin of 21.2%), after a 51% gross margin on the products/services it sells. After all costs, taxes and interest, 2.1% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.7× equity), comfortably covers its short-term bills (2.4× current ratio), and is currently profitable.
Who at BMRN filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Friberg Gregory R | EVP, Chief R&D Officer | Shares withheld (tax) | $245,160.00 | Form 4 for Friberg Gregory R (opens sec.gov in a new tab) | |
| Plenge Robert M | Director | Grant / award | — | Form 4 for Plenge Robert M (opens sec.gov in a new tab) | |
| Davis George Eric | EVP, Chief Legal Officer | Open-market sale | $1,163,748.19 | Form 4 for Davis George Eric (opens sec.gov in a new tab) | |
| Countouriotis Athena | Director | Grant / award | — | Form 4 for Countouriotis Athena (opens sec.gov in a new tab) | |
| Walbert Timothy P | Director | Grant / award | — | Form 4 for Walbert Timothy P (opens sec.gov in a new tab) | |
| Ho Maykin | Director | Grant / award | — | Form 4 for Ho Maykin (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is BMRN's intrinsic value?
TickerWorth's blended fair value for BioMarin Pharmaceutical Inc. (BMRN) is $70.83 per share, versus a market price of $54.68 (priced within our range of $46.63 – $109.11).
Is BMRN overvalued or undervalued?
Priced within our range of $46.63 – $109.11 at $54.68. We don't call BMRN overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for BMRN?
A WACC of 6.2% and a terminal growth rate of 2.5%.
Is BioMarin Pharmaceutical stock undervalued?
TickerWorth's fair value for BioMarin Pharmaceutical Inc. (BMRN) is $70.83 against a market price of $54.68. Our read: Priced within our range of $46.63 – $109.11. This is a model estimate, not investment advice.
BioMarin Pharmaceutical (BMRN) DCF valuation and fair value
Our fair value for BioMarin Pharmaceutical Inc. (BMRN) is $70.83, built on a 6.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into BioMarin Pharmaceutical stock?
Today's price implies revenue growth of 18.1% a year for 5 years; our model assumes 11.8% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $54.68. A model estimate, not investment advice.
BioMarin Pharmaceutical (BMRN) insider trading
The most recent insider filing (SEC Form 4) for BioMarin Pharmaceutical Inc. (BMRN): Friberg Gregory R, EVP, Chief R&D Officer, shares withheld (tax) on 2026-09-30. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.